State Street Health Care Select Sector SPDR ETF (XLV)

Drug Pipeline Wins State Street Over on Healthcare

Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge

Q2 Earnings Preview: Tech & Energy Drive Growth Amid Healthcare Headwinds

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Not Just Tech: Invest in Innovation With Healthcare

Stocks Look Shaky, But This Sector is Booming (Biotech)

4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

3 Healthcare ETFs to Own in a Choppy Stock Market

Weak June Jobs Data Likely to Boost These ETF Areas

State Street Health Care ETF Tops Invesco Pharma on Cost and Size

Investors Are Rotating Into Healthcare. Here's Why.

SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns

Anxious About an AI Bubble? ETFs to Help Navigate the Risk

Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

ETF Ways to Navigate the 2026 Midterm Election Cycle

Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

Health Care ETFs: XLV Delivers Low Fees and Solid Returns